FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 337:1634-1635 November 27, 1997 Number 22 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Guilhot, F. PubMed Citation

To the Editor: Guilhot et al. (July 24 issue)¹ should be complimented for their study of the treatment of chronic myelogenous leukemia. However, we were impressed by the toxicity of combination therapy with cytarabine and interferon alfa-2b. Their results suggest that an additional 15 percent of patients (18 of 118) given interferon alfa-2b alone can achieve a major cytogenetic response when crossed over to combination therapy. These patients were selected because they did not achieve a complete hematologic response after six months of therapy with interferon alfa-2b alone. Thus, a major cytogenetic response may be achieved in 41 percent of . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Schiff, E., Eisenberg, E. (2003). Can Quantitative Sensory Testing Predict the Outcome of Epidural Steroid Injections in Sciatica? A Preliminary Study. Anesth. Analg. 97: 828-832 [Abstract] [Full Text]